By Dr. Kamal Kant Kohli,Ruchika Sharma

Copyright medicaldialogues

Noida: Jubilant Pharmova Limited has announced the completion of the United States Food and Drug Administration (USFDA) Post-marketing Adverse Drug Experience (PADE) inspection of Jubilant Cadista Pharmaceuticals Inc, USA, a subsidiary of its wholly owned subsidiary Jubilant Pharma Limited.The inspection closed with no observations.”The above inspection concluded with zero observations, reaffirming Jubilant commitment to maintaining the highest standards of quality, safety, and compliance,” the company stated.Read also: USFDA issues 4 observations for Jubilant Generics Roorkee facilityJubilant Pharma Limited, a Company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of 45 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through multiple manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Read also: Jubilant Ingrevia appoints Sonia Dharap as Vice President – Sales, Business Development (US)